• 1
    Prevention of Liver Cancer. WHO Technical Report Series. Geneva, Switzerland: World Health Organization, 1983: 691.
  • 2
    Lin TM, Chen CJ, Tsai SF, et al. Hepatoma in Taiwan. J Natl Public Health Assoc (ROC) 1988; 8: 91100.
  • 3
    Chen CH, Chen DS. Hepatocellular carcinoma: 30-year experience in Taiwan. J Formos Med Assoc 1992; 91 (Suppl. 3): S187202.
  • 4
    Lotze MT, Flickinger JC, Carr BI. Hepatobiliary neoplasms. In: DeVita, VT, Hellman, S, Rosenberg, SA, eds. Cancer: Principle and Practice of Oncology, 4th edn. Philadelphia, USA: J. B. Lippincott Company, 1993: 883914.
  • 5
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 91828.
  • 6
    Lai CL, Lam KC, Wong KP, et al. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer 1981; 47: 274655.
  • 7
    Nerenstone S, Friedman F. Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 1987; 16: 60312.
  • 8
    Lai CL, Wu PC, Chan GCB, et al. Doxorubicin versus no antitumour therapy in inoperable hepatocellular carcinoma. Cancer 1988; 62: 47983.
  • 9
    Ikeda K, Saitoh S, Tsubota A. Diagnosis and follow-up of small hepatocellular carcinoma with selective intra-arterial digital subtraction angiography. Hepatology 1993; 17: 10037.
  • 10
    Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumour. Hepatology 1996; 23: 45564.
  • 11
    Yamaguchi R, Yano H, Iemura A. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 6877.
  • 12
    Folkman J. Tumour angiogenesis: therapeutic implication. N Engl J Med 1971; 285: 11826.
  • 13
    Kerbe RS. Inhibition of tumour angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 316.
  • 14
    McBride WG. Thalidomide and congenital abnormalities. Lancet 1968; 2: 1358.
  • 15
    D'Amato RJ, Loughnan MS, Flynn E. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 40825.
  • 16
    Kruse FE, Joussen AM, Rohrschneider K. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 4616.
  • 17
    Figg WD, Dahut W, Duray P, et al. Randomized phase II study of thalidomide, an angiogenesis inhibitor, in androgen-independent prostate cancer. Clin Cancer Res 2001; 7: 188893.
  • 18
    Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18: 70815.
  • 19
    Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 27107.
  • 20
    Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593602.
  • 21
    Singhal S, Mehta J, Desikan R, et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 156571.
  • 22
    Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2000; 98: 4924.
  • 23
    Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001; 98: 95865.
  • 24
    Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91: 12817.
  • 25
    Libutti SK, Pluda JM. Antiangiogenesis: clinical applications. In: Rosenberg, SA, ed. Principles and Practice of the Biologic Therapy of Cancer, 3rd edn. Baltimore, MD, USA: Lippincott Williams & Wilkins, 2000: 84464.
  • 26
    Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approach needed? J Clin Oncol 2001; 19: 26572.
  • 27
    Gradishar WJ. Endpoints for determination of efficacy of antiangiogenic agents in clinical trials. In: Tricher, BA, ed. Antiangiogenic Agents in Cancer Therapy. Totowa, NJ, UAA: Humana Press Inc., 2001: 34153.
  • 28
    Chen DS, Sung JL, Sheu JC, et al. Serum α-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 14049.
  • 29
    Sheu JC, Sung JL, Chen DS, et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical applications. Gastroenterology 1985; 89: 25966.
  • 30
    Johnson PJ, Williams R. Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Natl Cancer Inst 1980; 64: 132932.
  • 31
    Hsieh MY, Lu SN, Wang LY, et al. Alpha-fetoprotein in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. J Gastroenterol Hepatol 1992; 7: 6147.
  • 32
    Rustin GL. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187s93s.
  • 33
    Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-specific Antigen Working Group. J Clin Oncol 1999; 17: 34617.
  • 34
    Kanematsu M, Oliver JH, Baron RL, et al. Hepatocellular carcinoma: the role of biphasic contrast enhanced CT versus CT during arterial portography. Radiology 1997; 205: 7580.
  • 35
    Laghi A, Iannaccone R, Rossi P, et al. Hepatocellular carcinoma: detection with triple-phase multi-detector row helical CT in patients with chronic hepatitis. Radiology 2003; 226: 5439.
  • 36
    Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 20714.
  • 37
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 45781.
  • 38
    Cox DR. Regression model and life tables (with discussion). J R State Soc B 1972; 34: 187200.
  • 39
    The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 7515.
  • 40
    Hsu C, Chen CN, Chen LT, et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003; 65: 2429.
  • 41
    Wang TE, Kao CR, Lin SC, et al. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10: 64953.
  • 42
    Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005; 103: 11925.
  • 43
    Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103: 74955.
  • 44
    Wadler S. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Cancer 2005; 103: 14.
  • 45
    Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 167681.
  • 46
    Liaw YF, Tai DI, Chen TJ, et al. Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986; 6: 1337.
  • 47
    Siemeister G, Schirner M, Weindel K, et al. Two independent mechanisms essential for tumour angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 318591.
  • 48
    Kerbel RS. Tumour angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 50515.
  • 49
    Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 187886.
  • 50
    Slaton JW, Perrotte P, Inoue K, et al. Interferon-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 272634.
  • 51
    Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 182734.
  • 52
    Braun AG, Harding FA, Weinreb SL. Teratogen metabolism: thalidomide activation is mediated by cytochrome p450. Toxicol Appl Pharmacol 1986; 82: 1759.